The European Society of Cardiology advances prevention, diagnosis and management of heart disease through guidelines, education and research for ~100,000 members.
AstraZeneca has announced that Wainua, its gene-silencer drug for transthyretin-mediated amyloid cardiomyopathy, did not meet its primary endpoint in a phase 3 trial. The news triggers a sharp stock drop and prompts investors to rethink the company’s long-term growth targets and the strength of its pipeline.
A long-running study has found that men with cardiovascular disease face a higher lifetime cancer risk than women with the same condition. The analysis, drawn from EPIC-Norfolk data, identifies smoking, obesity and heavy drinking as primary drivers, with higher risks for gastric, oesophageal and lung cancers. The research calls for targeted risk management and prevention.
Largest study to date shows higher blood levels of xylitol are associated with a greater risk of major cardiovascular events. The Berlin-led research, presented at the ESC congress, analyzed 17,710 people over six years and found the highest quartile had a 57% higher risk than the lowest. The association persisted across age, sex and common risk factors.